Inhaled Nitric Oxide Market Size Analysis and Top Companies
The global inhaled nitric oxide market size is projected to hit around USD 2.21 billion by 2033 form USD 1.03 billion in 2023 and with at a CAGR of 7.95%. The major players operating in the inhaled nitric oxide market are Vero Biotech LLC, International Biomedical, Bellerophon Therapeutics, Mallinckrodt Pharmaceuticals, Praxair, Inc., SLE, Getinge AB, and Others.
Market Report Coverage
| Report Coverage |
Details |
| Market Size in 2024 |
USD 1.11 Billion |
| Market Size by 2034 |
USD 2.39 Billion |
| Growth Rate from 2024 to 2034 |
CAGR of 7.95% |
| Largest Market |
North America |
| Fastest Growing Market |
Europe |
| Base Year |
2023 |
| Forecast Period |
2024 to 2034 |
| Segments Covered |
By Product Type and By Application |
| Regions Covered |
North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Inhaled Nitric Oxide Key Players
- Vero Biotech LLC
- International Biomedical
- Bellerophon Therapeutics
- Mallinckrodt Pharmaceuticals
- Praxair, Inc.
- SLE
- Getinge AB
Recent Developments
- In May 2023, Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology firm advancing new biotherapeutics throughout its proprietary Anticalin technology stage for a respiratory disorder, and cancer, declared the safety survey of 10 mg dry powder amount safety cohort from the latest multi-center placebo-organized phase 2a study.
- In February 2023, Vero Biotech declared that the FDA accepted Genosyl, second-generation, for rebreathing anesthesia in the functional room setting. Vero Biotech made Genosyl for the delivery of inhaled nitric oxide, which underlines the second-generation Genosyl. The third-generation device recently obtained FDA approval has yet to be verified with rebreathing anesthesia.
We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344
